| Literature DB >> 24900672 |
Yuri Bolshan1, Matthäus Getlik2, Ekaterina Kuznetsova1, Gregory A Wasney1, Taraneh Hajian1, Gennadiy Poda2, Kong T Nguyen1, Hong Wu1, Ludmila Dombrovski1, Aiping Dong1, Guillermo Senisterra1, Matthieu Schapira1, Cheryl H Arrowsmith1, Peter J Brown1, Rima Al-Awar2, Masoud Vedadi1, David Smil1.
Abstract
The WD40-repeat protein WDR5 plays a critical role in maintaining the integrity of MLL complexes and fully activating their methyltransferase function. MLL complexes, the trithorax-like family of SET1 methyltransferases, catalyze trimethylation of lysine 4 on histone 3, and they have been widely implicated in various cancers. Antagonism of WDR5 and MLL subunit interaction by small molecules has recently been presented as a practical way to inhibit activity of the MLL1 complex, and N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides were reported as potent and selective antagonists of such an interaction. Here, we describe the protein crystal structure guided optimization of prototypic compound 2 (K dis = 7 μM), leading to identification of more potent antagonist 47 (K dis = 0.3 μM).Entities:
Keywords: MLL; SET1 methyltransferase complex; WDR5; peptide binding site; small molecule antagonists
Year: 2013 PMID: 24900672 PMCID: PMC4027439 DOI: 10.1021/ml300467n
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345